The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Abstract

The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2,626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara- group) and those administered Dara (Dara + group), the 1-year progression-free survival (1-year PFS) rates were 87.4% and 77.3% and the 1-year overall survival (1-year OS) rates were 96.7% and 90.0% in the two groups, respectively. In multivariate analysis, age < 65 years (p = 0.015), low ISS stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037) and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara- group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara + group were significantly inferior to those of the Dara- group.